Advances in Developing Small Molecule Drugs for Alzheimer's Disease
Wei Zhang1, Liujie Zhang1, Mingti Lv1,2
1School of Basic Medical Science, Xinxiang Medical University, Xinxiang, China.
Current Alzheimer Research
|August 13, 2024
Summary
Computer-aided drug design (CADD) offers innovative strategies for Alzheimer's disease (AD) treatment. This approach aims to reduce costs and improve the quality of life for AD patients.
Area of Science:
- Neuroscience
- Pharmacology
- Computational Chemistry
Background:
- Alzheimer's disease (AD) is a prevalent form of dementia, necessitating urgent advancements in prevention and treatment.
- Current therapeutic strategies face challenges, driving the need for novel approaches.
Purpose of the Study:
- To review the pathogenesis of Alzheimer's disease.
- To explore the latest developments in Computer-aided drug design (CADD) and small-molecule docking for AD drug discovery.
- To summarize the research status of small-molecule compounds targeting AD and discuss future drug development.
Main Methods:
- Review of existing literature on AD pathogenesis.
- Analysis of current trends in Computer-aided drug design (CADD) and molecular docking technologies.
- Examination of small-molecule compounds and their drug action targets for AD.
Main Results:
- Computer-aided drug design (CADD) presents a promising avenue for reducing medication costs and enhancing patient quality of life.
- Identification of key drug action targets is crucial for developing effective small-molecule compounds.
- Significant progress has been made in computational approaches for AD drug discovery.
Conclusions:
- CADD and advanced docking technologies offer new paradigms for Alzheimer's disease treatment.
- Continued research into small-molecule compounds and their targets is vital for future AD therapies.
- Integrating computational methods accelerates the development of more accessible and effective AD treatments.
Keywords:
Alzheime's diseasecomputer-aided drug design targetsforkhead box protein O1pathogenesis.small molecule drugsβ-amyloidMore Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
171
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
171
01:26Alzheimer's Disease: Overview
456
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
456
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
112
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
112
01:30Dementia
108
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
108
01:26Drug Discovery: Overview
7.7K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.7K
01:24Parkinson's Disease: Treatment
241
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
241